Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Barth and colleagues have recently reviewed the diagnosis of polycystic ovary. In their insightful examination, they conclude that the current diagnostic criteria are insufficiently robust for clinical research. In fact, I would argue that currently available diagnostic criteria at present are insufficiently robust even for clinical care. We should note that this argument has significant economic and health-care consequences. Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies of women, affecting between 7 and 10% of all reproductive-aged women, with significant associated morbidities. However, as for many other syndromes, the disorder is diagnosable only by a collection of signs and features, and no single test is available for its diagnosis. There are currently three principal definitions of PCOS in widespread use. The core group of patients diagnosable as having the disorder are those demonstrating: (1) clinical or biochemical evidence of hyperandrogenism; and (2) ovulatory dysfunction; after (3) exclusion of other similarly appearing disorders (e.g. non-classic adrenal hyperplasia, Cushing’s syndrome, androgen-secreting tumours, etc.). This definition was first described in the proceedings of a 1990 National Institutes of Health (NIH)-sponsored expert conference on the subject. A second expert conference was convened by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) in Rotterdam in May 2003, which defined the disorder as affecting any individual that had two out of the following three features: (1) clinical and/or biochemical hyperandrogenism; (2) ovulatory dysfunction or (3) polycystic ovarian morphology. Like the NIH 1990 criteria, the diagnosis of PCOS was one of exclusion and required ruling out similarly presenting disorders. This definition basically expanded the original NIH 1990 criteria by considering two additional phenotypes of the disorder, namely women who had ovulatory dysfunction and hyperandrogenism, but normal ovulation, and women who had ovulatory dysfunction and polycystic ovarian morphology, but no clinical or biochemical evidence of hyperandrogenism. Finally, the Androgen Excess Society convened an expert taskforce to review published literature and arrived at a somewhat more evidence-based contemporary definition of the disorder. The recommendations of this taskforce represented a compromise between the NIH 1990 and the Rotterdam 2003 criteria in that they suggested that PCOS be defined by the presence of: (1) clinical and/or biochemical hyperandrogenism; (2) ovarian dysfunction, including ovulatory dysfunction and/or polycystic ovarian morphology; and (3) the exclusion of related or similarly appearing disclosures. What criteria to use for defining PCOS has significant implications for patient care, clinical research and public health. For example, the prevalence of PCOS as defined by the NIH 1990 criteria appears to be approximately 6.5% among reproductive-aged women. Alternatively, the prevalence of the disorder as defined by the Rotterdam 2003 criteria could be almost twice as high. Use of a broader definition could make it more difficult to complete meaningful research on PCOS. Most affected would be large populational genetic studies, whose ability to detect the role of candidate genes is predicated on the inclusion of large numbers of relatively homogeneous patients. Comparability between studies is also detrimentally affected by the great variability in potential phenotypes that are included in different studies. Finally, clinical practice, diagnosis and counselling will be affected by the criteria selected, as the incidence of associated morbidities with PCOS, such as insulin resistance and risk of diabetes, are more prevalent with certain phenotypes of PCOS. Notwithstanding the ongoing debate regarding which specific criteria should be used for diagnosing PCOS, it is clear that a much more fundamental problem has been mostly ignored and has been brought to our attention by Dr Barth and his colleagues. They eloquently note that if the features themselves are not well-defined, meaningful use of the proposed diagnostic criteria are severely hampered. For example, biochemical evidence of hyperandrogenism is a criterion that has been present in all three currently used definitions of PCOS. However, what does this exactly mean? We need to clearly define which androgens are being measured. Should we include total testosterone (T)? Or free T? Or DHEAS? Or androstenedione? Or other lesserknown androgen metabolites? Should we define biochemical hyperandrogenism as the collection or combination of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176
Self-citationAndrogen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citationUltrasound assessment of the polycystic ovary: international consensus definitions
Balen, A. H., Laven, J. S. E., Tan, S.-L., & Dewailly, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg044 · Cited by 1,015
Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0628 · Cited by 537
Self-citation
Cited by
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
“Alternatively, insensitive, qualitative, subjective, and vaguely defined phenotypes are important barriers to the development of a greater understanding of the molecular biology and genetics underlying these disorders, including PCOS (301).”
BackgroundSelf-citationYildiz, B. O., Bolour, S., Woods, K., Moore, A., & Azziz, R. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp024 · Cited by 395
Self-citationAdrenal Androgens and Androgen Precursors-Definition, Synthesis, Regulation and Physiologic Actions
Turcu, A., Smith, J. M., Auchus, R., & Rainey, W. E. (2014) · Comprehensive physiology · doi:10.1002/cphy.c140006 · Cited by 113
“Patients present with elevated serum androgen levels and/or abnormal hair growth (hirsutism), and they have 8 or fewer menses per year (indicating oligo-/anovulation) (12).”
Metadata
- Authors
- Azziz, R.
- Venue
- Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Publisher
- SAGE Publications
- Published
- 2008-01
- Volume
- 45
- Issue
- 1
- Pages
- 3-5
- ISSN
- 0004-5632 (ISSN-L)
- 1758-1001
- OpenAlex
- W2136656557
- Cited by
- 11
- References
- 4
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1258/acb.2007.007198
- The paper
- Azziz, R. (2008). Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1258/acb.2007.007198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.